Home   中文简体 中文繁體 
Company News Products R&D Investor relationship Human Resource Contact Us
 
 
 
News
 
FDZJ has transferred rights of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection, which was independently developed by FDZJ, to a third-party   2019-03-14 16:20
        FDZJ has transferred rights of Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection, which was independently developed by FDZJ, to a third-party.
Links  |  SiteMap  |  Privacy Copyright© Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co.,Ltd. 2007
(沪)-非经营性-2019-0143    沪ICP备10027510号-1